Chymotrypsin
Samson-Med OAO
1487 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Chymotrypsin is a proteolytic enzyme preparation derived from the pancreas of cattle.
Hydrolyzes proteins and peptones to form relatively low molecular weight peptides, cleaves bonds formed by aromatic amino acid residues (tyrosine, tryptophan, phenylalanine, methionine).
In medical practice, the use of chymotrypsin is based on the specific peculiarities of cleaving necrotic tissue and fibrinous formations, thinning viscous secrets and exudates, and, when administered intramuscularly, have an anti-inflammatory effect.
Indications
- Suppressive diseases of the respiratory system: tracheitis, bronchitis, bronchiectasis, pneumonia, lung abscesses, atelectasis, exudative pleurisy, bronchial asthma.
- In the treatment of burns, pressure sores, purulent wounds, thrombophlebitis.
- In ophthalmology: with fresh extensive thrombosis of the central retinal vein, acute obstruction of the central retinal artery, opacities of the vitreous body of traumatic and inflammatory origin, cataract extraction.
- In otolaryngology: with purulent sinusitis, subacute laryngotracheitis, after tracheostomy to facilitate the removal of thick viscous exudate, with acute, subacute, purulent, chronic otitis media and eustachitis with viscous exudate.
Composition
1 bottle contains:
Active substance: chymotrypsin - 10 mg.
No customer reviews for the moment.
Dosage and Administration
For intramuscular administration, immediately before use, 0.005 g of the drug is dissolved in 1-2 ml of sterile 0.9% sodium chloride solution or 0.5-2% procaine solution.
The course of treatment is 6-15 injections.
For respiratory diseases: the drug is used intramuscularly in doses of 5-10 mg per day for 10-12 days, it may be combined with the use of chymotrypsin aerosol in 5% aqueous solution in an amount of 3-4 ml. After 7-10 days, the treatment can be repeated.
In the treatment of burns and bedsores: Chymotrypsin in a dose of 20 mg is dissolved in 20 ml of a 0.25% solution of procaine and a thin needle is injected under a scab with several injections.
In the treatment of purulent wounds: purulent wound surfaces impose sterile wipes moistened with a solution of 0.025-0.05 g of chymotrypsin in 10-50 ml of a 025% procaine solution for 8 hours. For the treatment of purulent wounds, intramuscular injections of the drug are combined with local treatment of the wound with tampons moistened with a 5% aqueous solution of chymotrypsin.
With thrombophlebitis: the drug is administered intramuscularly in a dose of 5–10 mg daily for 7–10 days.
For cataract extraction: Chymotrypsin at a dilution of 1: 5000 is introduced into the posterior chamber of the eye, followed by washing the anterior chamber of the eye with a 0.9% sodium chloride solution 4 minutes after drug administration.
In the treatment of thrombosis of the central vein of the retina, acute obstruction of the central artery of the retina: Chymotrypsin is administered subconjunctivally at 0.2 ml of a 5% solution prepared in 1% procaine solution, 1-2 times a week.
With sinusitis: the drug is introduced into the corresponding cavity in the amount of 5-10 mg in 3-5 ml of 0.9% sodium chloride solution after puncture and washing the cavity.
With otitis media: drop in the ear with 0.5-1 ml of 0.1% solution of chymotrypsin in 0.9% sodium chloride solution.
When micro-operations on the ear to soften fibrinous formations in the middle ear: during surgery, a 0.1% chymotrypsin solution is injected into the cavity. Simultaneously, chymotrypsin should be administered intramuscularly at 2.5-5 mg 1-2 times a day.
The drug is diluted in 1-2 ml of a 0.25-0.5% solution of novocaine or 0.9% sodium chloride solution.
Adverse reactions
Maybe: allergic reactions.
Contraindications
It should not be injected into the bleeding cavities, applied to the ulcerated surfaces of malignant tumors in order to avoid the spread of the malignant process.
Carefully used in empyema tuberculosis ethnology (resorption of exudate may in some cases contribute to the development of bronchopleural fistula).
Special instructions
It is impossible to enter into the bleeding cavities, to apply on ulcerated surfaces of malignant tumors.
- Brand name: Chymotrypsin
- Active ingredient: Chymotrypsin
- Dosage form: Lyophilisate for preparation of solution for injections and local application
- Manufacturer: Samson-Med OAO
- Country of Origin: Russia
Studies and clinical trials of Chymotrypsin (Click to expand)
- Low Trypsin and Chymotrypsin Inhibitor Mutants in Winged Bean(Psophocarpus tetragonolobus (L) DC)
- Isolation and characterisation of four trypsin-chymotrypsin inhibitors from lentil seeds
- Improved protein free energy calculation by more accurate treatment of nonbonded energy: Application to chymotrypsin inhibitor 2, V57A
- Refined crystal structure (2.3 Å) of a double-headed winged bean α-chymotrypsin inhibitor and location of its second reactive site
- Conformational dynamics of chymotrypsin inhibitor 2 by coarse-grained simulations
- Enzyme-polyelectrolyte complexes in water-ethanol mixtures: Negatively charged groups artificially introduced into α-chymotrypsin provide additional activation and stabilization effects
- Thermobarostability of α-chymotrypsin in reversed micelles of aerosol OT in octane solvated by water-glycerol mixtures
- Stability and activity modulation of chymotrypsins in AOT reversed micelles by protein–interface interaction: Interaction of α-chymotrypsin with a negative interface leads to a cooperative breakage of a salt bridge that keeps the catalytic active conformation (Ile16–Asp194)
- Mass transfer studies on immobilized α-chymotrypsin biocatalysts prepared by deposition for use in organic medium
- Large acceleration of α-chymotrypsin-catalyzed dipeptide formation by 18-crown-6 in organic solvents
- Adsorption and enzyme (β-galactosidase and α-chymotrypsin): Immobilization properties of gel fiber prepared by the gel formation of cellulose acetate and titanium iso-propoxide
- Modeling of enzymatic reactions in vesicles: The case of α-chymotrypsin
- Kinetic analysis of deactivation of immobilized α-chymotrypsin by water-miscible organic solvent in kyotorphin synthesis
- Effect of mass-transfer limitations on the selectivity of immobilized α-chymotrypsin biocatalysts prepared for use in organic medium
- Dynamics at the Active Site ofN-(4-Fluorophenyl)-N-(2,6-difluorophenyl) carbamoyl-α-chymotrypsin
- Analysis of electrostatic and hydrophobic complementarities between chymotrypsin and avian ovomucoid third domains using molecular electrostatic potential: Effect of residue replacements
- Uniform poly(isopropylacrylamide) gel beads for immobilization of α-chymotrypsin
- A diffusion-reaction model for α-chymotrypsin carrying uniform thermosensitive gel beads
- Immobilization of α-chymotrypsin to a temperature-responsive reversibly soluble–insoluble oligomer based on N-isopropylacrylamide
- Immobilization of α-chymotrypsin in thermally reversible isopropylacrylamide-hydroxyethylmethacrylate copolymer gel
- Some recent developments in the preparation of novel recognition systems: A recognition site for the selective catalysis of an aldol condensation using molecular imprinting and specific affinity motifs for α-chymotrypsin using a phage display peptide library
- Crystal structure of the bovine α-chymotrypsin:kunitz inhibitor complex. An example of multiple protein:protein recognition sites
- Purification of substance P endopeptidase (SPE) activity in human spinal cord and subsequent comparative studies with SPE in cerebrospinal fluid and with chymotrypsin
- Characterization and distribution of chymotrypsin-like and other digestive proteases in Colorado potato beetle larvae
8 other products in the same category:
arrow_upward